← Back to Clinical Trials
Recruiting NCT07069218

NCT07069218 Hydroxyapatite Toothpastes and Enamel Remineralization:

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07069218
Status Recruiting
Phase
Sponsor University of Pavia
Condition Enamel Hypomineralization
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-07-25
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Biorepair® Total Protection Plus ToothpasteBioniq® Toothpaste

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-07-25 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized controlled clinical trial aims to evaluate the efficacy of two commercially available toothpastes containing hydroxyapatite in the remineralization of early enamel lesions. The study compares Biorepair® Total Protection Plus, which contains biomimetic microRepair particles, with Bioniq® Repair, a conventional hydroxyapatite-based toothpaste. Forty participants will be randomly assigned to either the trial group (Biorepair®) or the control group (Bioniq®), and both groups will receive quarterly professional dental cleanings and use the assigned toothpaste twice daily for 6 months. The primary outcome is the change in enamel demineralization, assessed by DIAGNOdent Pen scores, in permanent molar fissures and upper central incisors. Secondary outcomes include enamel integrity assessed by DIAGNOcam imaging and ICDAS scores, as well as changes in dental sensitivity (Schiff Air Index), erosive wear (BEWE Index), plaque accumulation (Plaque Index), gingival inflammation (Bleeding Index), and extrinsic stains (Modified Lobene Stain Index). Patient satisfaction will also be evaluated at the end of the study using a self-administered questionnaire. This study will help determine whether biomimetic hydroxyapatite offers superior benefits in maintaining enamel health compared to conventional formulations, supporting evidence-based preventive strategies in dental care.

Eligibility Criteria

Inclusion Criteria: * Subjects aged between 6 and 18 years * Ability to understand and follow instructions in Italian or English * Signed written informed consent provided by the parent/legal guardian and assent from the minor * Good cooperation and adherence to clinical instructions * Fully erupted permanent first molars and upper central incisors in good general condition * DIAGNOdent Pen baseline values in the C1 (0-12) or C2 (13-24) range Exclusion Criteria: * DIAGNOdent Pen values greater than 25 * Ongoing systemic antibiotic therapy * Presence of sealants or composite restorations on first permanent molars or upper central incisors * Severe enamel alterations such as molar-incisor hypomineralization (MIH), fluorosis, or extensive white/brown spot lesions * Poor motivation or limited compliance with study procedures

Contact & Investigator

Central Contact

Andrea Scribante, Associate Professor

✉ andrea.scribante@unipv.it

📞 +39 0382516223

Principal Investigator

Andrea Scribante, Associate Professor

PRINCIPAL INVESTIGATOR

University of Pavia

Frequently Asked Questions

Who can join the NCT07069218 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Enamel Hypomineralization. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07069218 currently recruiting?

Yes, NCT07069218 is actively recruiting participants. Contact the research team at andrea.scribante@unipv.it for enrollment information.

Where is the NCT07069218 trial being conducted?

This trial is being conducted at Pavia, Italy.

Who is sponsoring the NCT07069218 clinical trial?

NCT07069218 is sponsored by University of Pavia. The principal investigator is Andrea Scribante, Associate Professor at University of Pavia. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology